Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

COVID-19 2Severe Acute Respiratory Syndrome 1Neoplasms 1Mastocytosis 1Hypersensitivity 1

Interventions

BNT162 Vaccine 22019-nCoV Vaccine mRNA-1273 2tocilizumab 1sotrovimab 1proxalutamide 1bemcentinib 1Therapeutics 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Sodium Chloride 1Radiotherapy 1Patient Reported Outcome Measures 1Janus Kinase Inhibitors 1Influenza Vaccines 1Hydroxychloroquine 1HuMax-IL8 1Gelsolin 1Diagnostic Tests, Routine 1Decision Support Techniques 1COVID-19 Vaccines 1Blood Specimen Collection 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × COVID-19 × BNT162 Vaccine × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

NCT05016622 2024-07-31

Booster Dose Trial

Montefiore Medical Center

Phase 2 Terminated
106 enrolled 39 charts

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡